Grant Number:	5U01CA088160-09 Interpret this number
Primary Investigator:	Etzioni, Ruth
Organization:	Fred Hutchinson Cancer Research Center
Project Title:	Modeling Us Prostate Cancer Trends: Psa, Treatment & Ra*
Fiscal Year:	2009

DESCRIPTION (provided by applicant): This study aims to determine the population impact of changing strategies for prostate cancer control, by linking trends in disease incidence and mortality with trends in screening and treatment. The advent of PSA screening has transformed the way in which prostate cancer is detected and managed in the US. Today, the majority of prostate cancers in this country are screen-detected and localized. Increasing numbers of newly-diagnosed cases are being treated with hormone suppression therapy (HT), which has traditionally been reserved for advanced tumors. Cause-specific survival among prostate cancer cases has increased dramatically, but the real increase in life expectancy during the PSA era remains unclear. How have advances in screening and treatment contributed to prostate cancer death rates that have fallen by almost 30 percent since the early 1990s? And can racial disparities in patterns of care explain why mortality declines among African Americans are, only two-thirds of those among whites? We will use surveillance modeling to address these questions, building on our previous CISNET work, which modeled PSA screening. Our methods will combine simulation models and maximum likelihood analysis to address the following Specific Aims: (1) Estimate the real improvement in life expectancy among prostate cancer cases during the PSA era; (2) Quantify the contributions to mortality declines of PSA screening and HT, and evaluate whether the benefit of screening given growing use of HT exceeds the benefit that would be expected under standard therapies; (3) Determine whether racial differences in PSA screening and HT can account for the different mortality declines experienced by whites and African Americans; and (4) Address whether disease natural history differs according to race, by estimating lead times associated with PSA screening that are consistent with incidence trends in whites and African Americans. Our models will require reliable estimates of trends in screening and treatment, which we will obtain using SEER-Medicare data, as well as patient claims data from a large HMO based in Northern California. Through this work, our study promises to shed light on two of the most active controversies in prostate cancer research: the value of PSA screening versus advances in prostate cancer treatment, and the link between disparities in care and racial differences in prostate cancer outcomes.




Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
Authors: Pataky R. , Gulati R. , Etzioni R. , Black P. , Chi K.N. , Coldman A.J. , Pickles T. , Tyldesley S. , Peacock S. .
Source: International Journal Of Cancer, 2014-08-15 00:00:00.0; 135(4), p. 939-47.
EPub date: 2014-08-15 00:00:00.0.
PMID: 24443367
Related Citations

Measurement Equivalence Using A Mixed-mode Approach To Administer Health-related Quality Of Life Instruments
Authors: Broering J.M. , Paciorek A. , Carroll P.R. , Wilson L.S. , Litwin M.S. , Miaskowski C. .
Source: Quality Of Life Research : An International Journal Of Quality Of Life Aspects Of Treatment, Care And Rehabilitation, 2014 Mar; 23(2), p. 495-508.
PMID: 23943258
Related Citations

Patient Demographics, Quality Of Life, And Disease Features Of Men With Newly Diagnosed Prostate Cancer: Trends In The Psa Era
Authors: Glass A.S. , Cowan J.E. , Fuldeore M.J. , Cooperberg M.R. , Carroll P.R. , Kenfield S.A. , Greene K.L. .
Source: Urology, 2013 Jul; 82(1), p. 60-5.
PMID: 23706257
Related Citations

Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening.
Authors: Etzioni R. , Gulati R. , Cooperberg M.R. , Penson D.M. , Weiss N.S. , Thompson I.M. .
Source: Medical Care, 2013 Apr; 51(4), p. 295-300.
PMID: 23269114
Related Citations

Primary Treatments For Clinically Localised Prostate Cancer: A Comprehensive Lifetime Cost-utility Analysis
Authors: Cooperberg M.R. , Ramakrishna N.R. , Duff S.B. , Hughes K.E. , Sadownik S. , Smith J.A. , Tewari A.K. .
Source: Bju International, 2013 Mar; 111(3), p. 437-50.
PMID: 23279038
Related Citations

Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Authors: Gulati R. , Gore J.L. , Etzioni R. .
Source: Annals Of Internal Medicine, 2013-02-05 00:00:00.0; 158(3), p. 145-53.
PMID: 23381039
Related Citations

Factors Associated With Satisfaction With Prostate Cancer Care: Results From Cancer Of The Prostate Strategic Urologic Research Endeavor (capsure)
Authors: Resnick M.J. , Guzzo T.J. , Cowan J.E. , Knight S.J. , Carroll P.R. , Penson D.F. .
Source: Bju International, 2013 Feb; 111(2), p. 213-20.
PMID: 22928860
Related Citations

The Prostate Cancer Conundrum Revisited: Treatment Changes And Prostate Cancer Mortality Declines
Authors: Etzioni R. , Gulati R. , Tsodikov A. , Wever E.M. , Penson D.F. , Heijnsdijk E.A. , Katcher J. , Draisma G. , Feuer E.J. , de Koning H.J. , et al. .
Source: Cancer, 2012-12-01 00:00:00.0; 118(23), p. 5955-63.
PMID: 22605665
Related Citations

Aspirin Use And The Risk Of Prostate Cancer Mortality In Men Treated With Prostatectomy Or Radiotherapy
Authors: Choe K.S. , Cowan J.E. , Chan J.M. , Carroll P.R. , D'Amico A.V. , Liauw S.L. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2012-10-01 00:00:00.0; 30(28), p. 3540-4.
PMID: 22927523
Related Citations

Vegetable And Fruit Intake After Diagnosis And Risk Of Prostate Cancer Progression
Authors: Richman E.L. , Carroll P.R. , Chan J.M. .
Source: International Journal Of Cancer, 2012-07-01 00:00:00.0; 131(1), p. 201-10.
PMID: 21823116
Related Citations

The Impact Of Plco Control Arm Contamination On Perceived Psa Screening Efficacy
Authors: Gulati R. , Tsodikov A. , Wever E.M. , Mariotto A.B. , Heijnsdijk E.A. , Katcher J. , de Koning H.J. , Etzioni R. .
Source: Cancer Causes & Control : Ccc, 2012 Jun; 23(6), p. 827-35.
PMID: 22488488
Related Citations

Biopsy Follow-up Of Prostate-specific Antigen Tests
Authors: Zeliadt,S.B. , Buist,D.S. , Reid,R.J. , Grossman,D.C. , Ma,J. , Etzioni,R. .
Source: American Journal Of Preventive Medicine, 2012 Jan; 42(1), p. 37-43.
PMID: 22176844
Related Citations

Long-term Projections Of The Harm-benefit Trade-off In Prostate Cancer Screening Are More Favorable Than Previous Short-term Estimates
Authors: Gulati R. , Mariotto A.B. , Chen S. , Gore J.L. , Etzioni R. .
Source: Journal Of Clinical Epidemiology, 2011 Dec; 64(12), p. 1412-7.
PMID: 22032753
Related Citations

Androgen Deprivation Therapy And Cardiovascular Risk
Authors: Punnen,S. , Cooperberg,M.R. , Sadetsky,N. , Carroll,P.R. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2011-09-10 00:00:00.0; 29(26), p. 3510-6.
PMID: 21844498
Related Citations

How Does Early Detection By Screening Affect Disease Progression? Modeling Estimated Benefits In Prostate Cancer Screening
Authors: Wever E.M. , Draisma G. , Heijnsdijk E.A. , de Koning H.J. .
Source: Medical Decision Making : An International Journal Of The Society For Medical Decision Making, 2011 Jul-Aug; 31(4), p. 550-8.
PMID: 21406620
Related Citations

What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models.
Authors: Gulati R. , Wever E.M. , Tsodikov A. , Penson D.F. , Inoue L.Y. , Katcher J. , Lee S.Y. , Heijnsdijk E.A. , Draisma G. , de Koning H.J. , et al. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2011 May; 20(5), p. 740-50.
PMID: 21546365
Related Citations

Calibrating disease progression models using population data: a critical precursor to policy development in cancer control.
Authors: Gulati R. , Inoue L. , Katcher J. , Hazelton W. , Etzioni R. .
Source: Biostatistics (oxford, England), 2010 Oct; 11(4), p. 707-19.
PMID: 20530126
Related Citations

Prostate-specific Antigen Screening In The United States Vs In The European Randomized Study Of Screening For Prostate Cancer-rotterdam
Authors: Wever E.M. , Draisma G. , Heijnsdijk E.A. , Roobol M.J. , Boer R. , Otto S.J. , de Koning H.J. .
Source: Journal Of The National Cancer Institute, 2010-03-03 00:00:00.0; 102(5), p. 352-5.
PMID: 20142584
Related Citations

Lead Time And Overdiagnosis In Prostate-specific Antigen Screening: Importance Of Methods And Context
Authors: Draisma G. , Etzioni R. , Tsodikov A. , Mariotto A. , Wever E. , Gulati R. , Feuer E. , de Koning H. .
Source: Journal Of The National Cancer Institute, 2009-03-18 00:00:00.0; 101(6), p. 374-83.
PMID: 19276453
Related Citations

Effect Of Population Trends In Body Mass Index On Prostate Cancer Incidence And Mortality In The United States
Authors: Fesinmeyer M.D. , Gulati R. , Zeliadt S. , Weiss N. , Kristal A.R. , Etzioni R. .
Source: Cancer Epidemiology, Biomarkers & Prevention : A Publication Of The American Association For Cancer Research, Cosponsored By The American Society Of Preventive Oncology, 2009 Mar; 18(3), p. 808-15.
PMID: 19258479
Related Citations

Modeling Nonhomogeneous Markov Processes Via Time Transformation
Authors: Hubbard,R.A. , Inoue,L.Y. , Fann,J.R. .
Source: Biometrics, 2008 Sep; 64(3), p. 843-50.
PMID: 18047532
Related Citations

Studies Of Prostate-cancer Mortality: Caution Advised
Authors: Etzioni R. , Feuer E. .
Source: The Lancet. Oncology, 2008 May; 9(5), p. 407-9.
PMID: 18452850
Related Citations

Estimating Lead Time And Overdiagnosis Associated With Psa Screening From Prostate Cancer Incidence Trends
Authors: Telesca D. , Etzioni R. , Gulati R. .
Source: Biometrics, 2008 Mar; 64(1), p. 10-9.
PMID: 17501937
Related Citations

Quantifying the role of PSA screening in the US prostate cancer mortality decline.
Authors: Etzioni R. , Tsodikov A. , Mariotto A. , Szabo A. , Falcon S. , Wegelin J. , DiTommaso D. , Karnofski K. , Gulati R. , Penson D.F. , et al. .
Source: Cancer Causes & Control : Ccc, 2008 Mar; 19(2), p. 175-81.
PMID: 18027095
Related Citations

Modeling Disease Progression with Longitudinal Markers.
Authors: Inoue L.Y. , Etzioni R. , Morrell C. , Müller P. .
Source: Journal Of The American Statistical Association, 2008; 103(481), p. 259-270.
PMID: 24453387
Related Citations

Cluster-based Network Model For Time-course Gene Expression Data
Authors: Inoue,L.Y. , Neira,M. , Nelson,C. , Gleave,M. , Etzioni,R. .
Source: Biostatistics (oxford, England), 2007 Jul; 8(3), p. 507-25.
PMID: 16980695
Related Citations

Trends In Treatment Costs For Localized Prostate Cancer: The Healthy Screenee Effect
Authors: Zeliadt,S.B. , Etzioni,R. , Ramsey,S.D. , Penson,D.F. , Potosky,A.L. .
Source: Medical Care, 2007 Feb; 45(2), p. 154-9.
PMID: 17224778
Related Citations

Survival Benefit Associated With Adjuvant Androgen Deprivation Therapy Combined With Radiotherapy For High- And Low-risk Patients With Nonmetastatic Prostate Cancer
Authors: Zeliadt,S.B. , Potosky,A.L. , Penson,D.F. , Etzioni,R. .
Source: International Journal Of Radiation Oncology, Biology, Physics, 2006-10-01 00:00:00.0; 66(2), p. 395-402.
PMID: 16904843
Related Citations

An Ecologic Study Of Prostate-specific Antigen Screening And Prostate Cancer Mortality In Nine Geographic Areas Of The United States
Authors: Shaw P.A. , Etzioni R. , Zeliadt S.B. , Mariotto A. , Karnofski K. , Penson D.F. , Weiss N.S. , Feuer E.J. .
Source: American Journal Of Epidemiology, 2004-12-01 00:00:00.0; 160(11), p. 1059-69.
PMID: 15561985
Related Citations

Racial Disparity In Primary And Adjuvant Treatment For Nonmetastatic Prostate Cancer: Seer-medicare Trends 1991 To 1999
Authors: Zeliadt,S.B. , Potosky,A.L. , Etzioni,R. , Ramsey,S.D. , Penson,D.F. .
Source: Urology, 2004 Dec; 64(6), p. 1171-6.
PMID: 15596192
Related Citations

Combining Longitudinal Studies Of Psa
Authors: Inoue,L.Y. , Etzioni,R. , Slate,E.H. , Morrell,C. , Penson,D.F. .
Source: Biostatistics (oxford, England), 2004 Jul; 5(3), p. 483-500.
PMID: 15208207
Related Citations

Race Independently Predicts Prostate Specific Antigen Testing Frequency Following A Prostate Carcinoma Diagnosis
Authors: Zeliadt,S.B. , Penson,D.F. , Albertsen,P.C. , Concato,J. , Etzioni,R.D. .
Source: Cancer, 2003-08-01 00:00:00.0; 98(3), p. 496-503.
PMID: 12879465
Related Citations

Overdiagnosis Due To Prostate-specific Antigen Screening: Lessons From U.s. Prostate Cancer Incidence Trends
Authors: Etzioni R. , Penson D.F. , Legler J.M. , di Tommaso D. , Boer R. , Gann P.H. , Feuer E.J. .
Source: Journal Of The National Cancer Institute, 2002-07-03 00:00:00.0; 94(13), p. 981-90.
PMID: 12096083
Related Citations

Discovering Subpopulation Structure With Latent Class Mixed Models
Authors: McCulloch C.E. , Lin H. , Slate E.H. , Turnbull B.W. .
Source: Statistics In Medicine, 2002-02-15 00:00:00.0; 21(3), p. 417-29.
PMID: 11813228
Related Citations

Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.
Authors: Etzioni R. , Berry K.M. , Legler J.M. , Shaw P. .
Source: Urology, 2002 Feb; 59(2), p. 251-5.
PMID: 11834397
Related Citations